We are live on ! Find out more
COLL icon

Collegium Pharmaceutical

157 hedge funds and large institutions have $646M invested in Collegium Pharmaceutical in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 52 increasing their positions, 68 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

219% more call options, than puts

Call options by funds: $628K | Put options by funds: $197K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.85% less ownership

Funds ownership: 108.09%107.24% (-0.85%)

9% less funds holding

Funds holding: 172157 (-15)

12% less capital invested

Capital invested by funds: $734M → $646M (-$88.4M)

24% less repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 68

32% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 25

Holders
157
Holders Change
-15
Holders Change %
-8.72%
% of All Funds
2.64%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
17
Increased
52
Reduced
68
Closed
25
Calls
$628K
Puts
$197K
Net Calls
+$431K
Net Calls Change
+$209K
Name Holding Trade Value Shares
Change
Change in
Stake
YCM
76
Yousif Capital Management
Michigan
$572K -$51.3K -3,050 -9%
Lazard Asset Management
77
Lazard Asset Management
New York
$554K +$249K +14,797 +90%
COPPSERS
78
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$549K +$19.6K +1,168 +4%
Bank of America
79
Bank of America
North Carolina
$543K -$455K -27,053 -47%
UBS AM
80
UBS AM
Illinois
$499K -$9.35K -556 -2%
Comerica Bank
81
Comerica Bank
Texas
$498K
Citigroup
82
Citigroup
New York
$488K -$267K -15,855 -37%
SOADOR
83
State of Alaska Department of Revenue
Alaska
$455K +$27.8K +1,650 +7%
T. Rowe Price Associates
84
T. Rowe Price Associates
Maryland
$453K +$24K +1,425 +6%
TRCT
85
Tower Research Capital (TRC)
New York
$452K +$421K +25,054 +5,166%
CS
86
Credit Suisse
Switzerland
$448K +$202 +12 +0%
Jane Street
87
Jane Street
New York
$443K +$421K +25,006 New
TPSF
88
Texas Permanent School Fund
Texas
$434K -$505 -30 -0.1%
D.E. Shaw & Co
89
D.E. Shaw & Co
New York
$432K -$1.79M -106,596 -81%
HAG
90
HighPoint Advisor Group
Illinois
$422K +$369K +21,906 New
H6H
91
Hightower 6M Holding
Kansas
$406K +$269 +16 +0.1%
NYLIM
92
New York Life Investment Management
New York
$406K +$385K +22,905 New
IFWM
93
Institute for Wealth Management
Colorado
$395K +$163K +9,711 +77%
EIP
94
Easterly Investment Partners
Massachusetts
$390K -$33.6K -2,000 -8%
MIM
95
MetLife Investment Management
New Jersey
$360K -$39.5K -2,350 -10%
DekaBank Deutsche Girozentrale
96
DekaBank Deutsche Girozentrale
Germany
$349K -$258K -15,320 -43%
AIG
97
American International Group
New York
$326K -$23.1K -1,375 -7%
Deutsche Bank
98
Deutsche Bank
Germany
$324K -$40.2K -2,390 -12%
MAM
99
Martingale Asset Management
Massachusetts
$292K +$6.61K +393 +2%
AB
100
Amalgamated Bank
New York
$291K -$7.59K -451 -3%

COLL Hedge Fund Activity: Q2 2022 in Review

157 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q2 2022, worth a combined $646M — down 12% from $734M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of COLL and 17 opened new positions — a net loss of 8 holders — while 68 trimmed existing stakes and 52 added.

The largest buyer was Principal Financial Group, adding an estimated $5.4M. The largest seller was Pacer Advisors, exiting entirely with an estimated $4.5M sold.

  • 157 institutional investors held Collegium Pharmaceutical (COLL) as of Q2 2022, down from 172 in Q1 2022.
  • Funds reported $646M of Collegium Pharmaceutical stock for Q2 2022, down 12% quarter-over-quarter.
  • 17 funds opened new Collegium Pharmaceutical positions in Q2 2022 and 25 closed out, a net change of -8 holders.
  • The largest Collegium Pharmaceutical buyer in Q2 2022 was Principal Financial Group, an estimated $5.4M added.
  • The largest Collegium Pharmaceutical seller in Q2 2022 was Pacer Advisors, an estimated $4.5M sold.

Based on aggregated 13F filings for Q2 2022.